Bervastatin

Drug Profile

Bervastatin

Alternative Names: LS 2904

Latest Information Update: 14 Apr 1999

Price : $50

At a glance

  • Originator Merck Sante
  • Class Antihyperlipidaemics
  • Mechanism of Action HMG-CoA reductase inhibitors; Thromboxane A2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Hyperlipidaemia

Most Recent Events

  • 14 Apr 1999 Bervastatin now appears to be in development with Merck KGaA
  • 11 Sep 1998 No-Development-Reported for Hyperlipidaemia in United Kingdom (Unknown route)
  • 08 Sep 1998 No-Development-Reported for Hyperlipidaemia in France (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top